Publication:
Factors associated with a lack of viral suppression in chronic hbv (CHB) patients after 8 years of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) followed by taf treatment

Simple item page
dc.contributor.authorGane, Edward J.
dc.contributor.authorButi, Maria
dc.contributor.authorFung, Scott K.
dc.contributor.authorChan, Henry Lik Yuen
dc.contributor.authorIzumi, Namiki
dc.contributor.authorChuang, Wan Long
dc.contributor.authorAhn, Sang Hoon
dc.contributor.authorMehta, Rajiv M.
dc.contributor.authorGürel, Selim
dc.contributor.authorAbramov, Frida
dc.contributor.authorYee, Leland J.
dc.contributor.authorWang, Hongyuan
dc.contributor.authorMateo, Roberto
dc.contributor.authorFlaherty, John F.
dc.contributor.authorMa, Xiaoli
dc.contributor.authorPan, Calvin Q.
dc.contributor.authorLim, Young-Suk
dc.contributor.authorMarcellin, Patrick
dc.contributor.buuauthorGÜREL, SELİM
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.
dc.contributor.researcheridJKF-2069-2023
dc.date.accessioned2024-10-15T10:47:11Z
dc.date.available2024-10-15T10:47:11Z
dc.date.issued2023-10-01
dc.descriptionBu çalışma, 10-14, Kasım 2023 tarihlerinde Boston[Amerika]’da düzenlenen Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) Kongresi‘nde bildiri olarak sunulmuştur.
dc.description.sponsorshipAmer Assoc Study Liver Dis
dc.identifier.endpageS520
dc.identifier.issn0270-9139
dc.identifier.issueSupplement 1
dc.identifier.startpageS519
dc.identifier.urihttps://hdl.handle.net/11452/46446
dc.identifier.volume78
dc.identifier.wos001094865401148
dc.indexed.wosWOS.SCI
dc.indexed.wosWOS.ISTP
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.journalHepatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGastroenterology & hepatology
dc.titleFactors associated with a lack of viral suppression in chronic hbv (CHB) patients after 8 years of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) followed by taf treatment
dc.typeMeeting Abstract
dspace.entity.typePublication
relation.isAuthorOfPublicationd7a9ea11-69fc-4122-a365-8fb2123512e6
relation.isAuthorOfPublication.latestForDiscoveryd7a9ea11-69fc-4122-a365-8fb2123512e6

Files

Collections

Yeni Yayınlar